Taichi Hara is a Professor at the Faculty of Human Sciences, Waseda University since 2017. Previously held positions at Gunma University (2010-2017) and the University of Pennsylvania (2009-2010). His research bridges autophagy , functional foods , and protein quality control in neurodegenerative diseases. Education: Ph.D. in Medicine from Kyushu University (2004). Research Themes focus on autophagy regulation by dietary compounds, mechanisms of protein accumulation in Charcot-Marie-Tooth disease and tauopathy, and applications of mTOR signaling in healthspan extension. His work connects food science with cellular degradation pathways and neurodegenerative disease modeling. Article Trends emphasize plant-derived compounds (isorhamnetin, bilberry anthocyanins) for autophagy modulation, mTORC2-GATA3 axis in lysosomal function, and mouse models for neurodegenerative disorders. Studies span hepatocyte protection , skin aging , and embryonic development . Professional Memberships include the Japanese Society for Food Science and Technology, Japanese Biochemical Society, and Japanese Society for Neurochemistry.
Dr. Alexander Haslberger is a Professor at the University of Vienna's Faculty of Life Sciences, Department of Nutritional Sciences, with an extensive research career spanning from 1985 to present. His work focuses at the intersection of nutritional science, molecular biology, and epigenetics, with particular emphasis on how diet influences human health through epigenetic mechanisms. With 165 publications to his name and leadership of multiple research projects, Haslberger has established himself as a leading researcher in personalized nutrition and gut microbiota interactions. Faculty of Life Sciences, Department of Nutritional Sciences 165 publications across 38 years (1985-2023) 4 major research projects completed 27 academic activities including lectures and presentations 6 media appearances discussing his research Haslberger's research primarily explores the epigenetic effects of nutrition on human health, with particular focus on gut microbiota composition, DNA methylation patterns, and microRNA expression. His fingerprint analysis shows strong expertise in Epigenetics (100%), Intestine Flora (88%), Microflora (82%), Methylation (58%), Faecalibacterium prausnitzii (58%), Interleukin 6 (54%), Probiotic research (49%), and Periplasm biology (47%). His work bridges molecular mechanisms with practical nutritional interventions, particularly examining how fasting, probiotics, and specific dietary components influence health outcomes through epigenetic regulation. Analysis of Haslberger's recent publications (2022-2025) reveals a clear trajectory toward personalized nutrition approaches, with increasing focus on sex-specific responses, biomarker development (particularly miRNA-based), and the integration of gut microbiome data into nutritional recommendations. His work connects fundamental epigenetic mechanisms with practical applications for healthy aging, depression management, and cancer prevention. The research demonstrates how dietary interventions like fasting, probiotic supplementation, and specific nutraceuticals can epigenetically modify gut microbiota composition and inflammatory responses. Visiting Professor award (2017) Haslberger has secured research funding for multiple projects including ROS damage studies (2013-2016), PHGEN II (2009-2012), and Advice on taking probiotics (2008-2011). His research activities include numerous lectures and presentations on topics such as fasting mimetics, gut microbiota composition, age-related inflammation, senolysis, and DNA stability. Media coverage of his work includes appearances in Kurier.at and OKTO TV discussing epigenetics, fasting, and microbiota research. While specific laboratory details aren't provided in the available information, Haslberger's research network shows extensive collaborations across multiple countries, with particular focus on epigenetic mechanisms related to nutrition, gut health, and aging. His work integrates molecular biology techniques with clinical nutrition approaches to develop personalized dietary recommendations based on individual epigenetic and microbiome profiles.
Prof. Dr. Olaf Kruse is a Professor at Bielefeld University in the Faculty of Biology, where he serves as Head of the Working Group on Algal Biotechnology & Bioenergy at the Center for Biotechnology (CeBiTec). He is also a Board member of CeBiTec and serves on various university committees including the Research Committee. His research focuses on harnessing microalgae as green cell factories for solar energy conversion into biomass, bioenergy, and high-value products. Dr. Kruse's work specifically targets understanding regulatory aspects of photosynthesis in microalgae and optimizing solar energy conversion into biofuels through advanced molecular biology approaches. His group employs Systems Biology strategies using omics technologies to elucidate regulatory networks of light harvesting and establish metabolic flow models for algal biofuel production pathways. Dr. Kruse's recent publications demonstrate a strong emphasis on genetic engineering of Chlamydomonas reinhardtii for enhanced production of valuable compounds including zeaxanthin, astaxanthin, and various terpenoids. His research integrates multiple approaches including CRISPR/Cas9 genome editing, metabolic pathway engineering, and development of novel cultivation techniques such as hydrogel immobilization systems. Young Scientist van't Hoff fund award of the Dutch Royal Society (2008) As an academic advisor, Dr. Kruse has mentored numerous researchers who frequently appear as co-authors on his publications, including Baier T, Jacobebbinghaus N, and Kneip J. His research has been supported through various national and international funding mechanisms including DFG Collaborative Research Centers and EU framework programs. Dr. Kruse leads the Algal Biotechnology & Bioenergy working group which operates within CeBiTec's technology platform, utilizing advanced omics technologies and bioinformatics support for their research.
Xiaoying Bian is a Professor of Pharmaceutical Biotechnology at the State Key Laboratory of Microbial Technology, Shandong University, where she has been employed since July 2015. She also serves as Supervisor of Doctorate Candidates and Supervisor of Master's Candidates. Her research focuses on harnessing microbial genetics to discover and engineer natural products with pharmaceutical potential through innovative genome editing technologies. Education: PhD in Pharmaceutical Biotechnology, Saarland University, Germany (2013) MS in Plant Protection, Northwest A&F University, China (2008) BS in Plant Protection, Northwest A&F University, China (2005) Dr. Bian's research centers on synthetic biology approaches for microbial natural products discovery. Her work develops genome editing and synthetic biology enabling technologies to unlock 'hidden' biosynthetic pathways in microbes. She investigates genome mining for novel natural products, biosynthetic engineering, and genome editing of microbes and microbiomes. Her research bridges microbiology, genetics, and pharmaceutical development to discover new drug leads from previously inaccessible microbial sources, with particular focus on non-model bacterial species that have been difficult to genetically manipulate. Dr. Bian's recent publications demonstrate a strong focus on genome editing technologies, particularly Recombineering and CRISPR-based systems, applied to microbial natural product discovery. Her work spans multiple bacterial genera including Burkholderia, Streptomyces, and Bacillus, with emphasis on nonribosomal peptide synthetases (NRPS), polyketide synthases (PKS), and siderophore biosynthesis. Her research shows increasing interdisciplinary collaboration with chemists, bioinformaticians, and ecologists, reflecting the complex nature of modern natural product discovery. Scientific Awards: 2022 The 13th Qingdao Youth Science and Technology Award 2019 Recipients of the Shandong Provincial Science Fund for Distinguished Young Scholars 2015 Qilu Youth Scholar Professor, Shandong University 2012 Arthur E. Schwarting Award for Best Paper in the Journal of Natural Products 2022 Natural Product Reports Emerging Investigator Lectureship Nomination Education Ministry '2019 Annual Outstanding Scientific Research Achievement Award' Natural Science Award Second Prize Dr. Bian has supervised numerous doctoral and master's students through their research in microbial biotechnology. Her laboratory has received significant funding including the Shandong Provincial Science Fund for Distinguished Young Scholars. She serves as Managing Editor for Engineering Microbiology journal and is on the editorial board of Microbiology Bulletin. Her research team includes postdoctoral fellows, PhD students, and master's students working collaboratively on microbial genome editing and natural product discovery projects, with several successful graduates now pursuing independent research careers. Dr. Bian leads a dynamic research team at the State Key Laboratory of Microbial Technology, comprising multiple postdoctoral researchers, doctoral candidates, and master's students. Her laboratory focuses on developing cutting-edge genome editing tools specifically tailored for non-model microorganisms, which has enabled the discovery of numerous novel natural products with pharmaceutical potential. The team maintains strong collaborations with researchers across China and internationally, particularly with institutions in Germany where Dr. Bian completed her doctoral studies, and has established itself as a leading center for microbial natural product research in China.
Ian S. Haworth is an Associate Professor and Vice Chair of Pharmacology and Pharmaceutical Sciences at the USC School of Pharmacy, University of Southern California. He joined USC in 1992 after completing his PhD in Physical Organic Chemistry at the University of Liverpool and postdoctoral research at Oxford University. His laboratory develops computational algorithms to study molecular associations in nucleic acids, proteins, and drug-target interactions. Education: PhD, University of Liverpool, UK (1986-1989) Postdoc, Oxford University, UK (1989-1992) BS, Manchester Metropolitan University His research integrates computational chemistry, biology, and pharmaceutical sciences to understand molecular dynamics in biological systems. Key areas include nucleic acid structure prediction, aptamer design, transporter protein analysis, and MHC-peptide-TCR associations. This work emphasizes accurate modeling of biological interfaces for therapeutic development. Haworth's recent publications focus on computational drug design (e.g., prodrug optimization, COX-2 inhibitors), structural biology (protein-nucleic acid complexes), and educational innovation (AI in pharmacy curriculum). His work consistently bridges computational predictions with experimental validation across therapeutic areas. Research Grants: NIH/NIGMS R01GM059297: PEPT1 Structure-Function (2000-2006) NIH/NCI R29CA064299: Polyamine Antitumor Complexes (1994-2000) He leads a computational lab developing tools like ALLNOX for biomolecular analysis and has contributed to transforming pharmacy education through case-based curricula. His team collaborates extensively across disciplines to study protein-membrane interactions, drug pharmacokinetics, and structural immunology.
